uniQure (QURE) Stock Price, News & Analysis

Company Overview

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) technology to deliver genetic material intended to address the underlying causes of disease, with research activities spanning neurological, neuromuscular, metabolic and cardiovascular conditions.

uniQure’s pipeline has included AMT-130, an investigational gene therapy for Huntington’s disease, as well as programs targeting other conditions such as amyotrophic lateral sclerosis and Fabry disease. The company also developed etranacogene dezaparvovec, an AAV-based gene therapy for hemophilia B that was licensed to CSL Behring and approved in the United States under the brand name Hemgenix. Earlier in its history, uniQure developed Glybera, which became the first gene therapy to receive regulatory approval in the European Union before its authorization was later withdrawn.

Founded in the Netherlands in 1998 as Amsterdam Molecular Therapeutics, uniQure has operations in the United States and Europe. The company is headquartered in Lexington, Massachusetts, and maintains research and development activities in the Netherlands. Matt Kapusta has served as uniQure’s chief executive officer since 2018.

Key Stats

• Today's Range: $44.04 to $45.30
• 50-Day Range: $36.66 to $51.05
• 52-Week Range: $8.73 to $71.50
• Volume: 1.24 million shs
• Average Volume: 1.11 million shs
• Market Capitalization: $3.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.00
• Consensus Rating: Moderate Buy

uniQure Stock Analysis - MarketRank™

uniQure scored higher than 71% of companies evaluated by MarketBeat, and ranked 225th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 14 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

uniQure has a consensus price target of $65.00, representing about 46.0% upside from its current price of $44.51.

Amount of Analyst Coverage

uniQure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for uniQure are expected to grow in the coming year, from ($3.82) to ($3.40) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of uniQure is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of uniQure is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

uniQure has a P/B Ratio of 13.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

14.93% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 9.42.

Change versus previous month

Short interest in uniQure has recently decreased by 8.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

uniQure does not currently pay a dividend.

Dividend Growth

uniQure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.92

News Sentiment

uniQure has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for uniQure this week, compared to 11 articles on an average week.

Search Interest

Only 6 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,712,415.00 in company stock.

Percentage Held by Insiders

4.65% of the stock of uniQure is held by insiders.

Percentage Held by Institutions

78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QURE
• CIK: 1590560
• Web: www.uniqure.com
• Phone: (120) 240-6000
• Fax: 31-20-566-9272
• Employees: 221
• Year Founded: 1868

Price Target and Rating

• Average Price Target for uniQure: $65.00
• High Price Target: $95.00
• Low Price Target: $28.00
• Potential Upside/Downside: +46.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.97 million
• Net Margins: -1,350.73%
• Pretax Margin: -1,313.04%
• Return on Equity: -111.96%
• Return on Assets: -29.01%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 10.01
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: $16.10 million
• Price / Sales: 191.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.19 per share
• Price / Book: 13.95

Miscellaneous

• Outstanding Shares: 69,370,000
• Free Float: 66,140,000
• Market Cap: $3.09 billion
• Optionable: Optionable
• Beta: 0.94